Adela, Inc. Secures $48 Million in Financing and Appoints Lisa Alderson as Interim CEO

Share This Post

Key Highlights

  • Adela, Inc. closes a $48 million financing round, bringing the total capital raised to $108 million.
  • Lisa Alderson steps in as interim Chief Executive Officer, succeeding Dr. Scott Bratman.
  • The financing includes contributions from existing investors like F-Prime Capital and OrbiMed, and new investor Labcorp.
  • Funds will be used to advance Adela’s technology platform, commercialize its MRD monitoring product, and further develop its multi-cancer early detection (MCED) product.
  • Adela’s platform was developed in collaboration with the University Health Network’s Princess Margaret Cancer Centre and Sinai Health System.

Source: PR Newswire

Notable Quotes

  • “Bringing this highly differentiated offering to market means oncologists and patients will have a better understanding of MRD and how it impacts patients with cancer,” – Shakti Ramkissoon, M.D., Ph.D., Vice President and Head of Medicine for Oncology at Labcorp
  • “We are excited to grow Adela to the next level with this new financing and the addition of Ms. Alderson’s expertise,” – David Scheer, Chairman of Adela’s Board of Directors
  • “This round of financing enables us to prepare operationally to commercialize products that hold the potential to improve care for millions of people with cancer,” – Lisa Alderson, Interim CEO, Adela

SoH's Take

Adela, Inc.’s recent financing success and leadership change signal a pivotal moment for the company. With a fresh capital infusion of $48 million, Adela is poised to make significant strides in the realm of early cancer detection and MRD monitoring. The appointment of Lisa Alderson, a seasoned leader with a track record of commercializing healthcare products, further strengthens Adela’s position in the market. Her previous roles at Genome Medical and Invitae showcase her capability to lead and innovate in the healthcare sector. With these developments, Adela is well-positioned to bring its groundbreaking technology to the forefront of the cancer care industry, potentially transforming the way cancer is detected and managed.

More To Explore

Total
0
Share